glp 1 mash Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - GLP-1 Fatty Liver MASH Approval:

Here's who is (and is not) an ideal candidate for medical weight loss:

Learn about the new Medicare Bridge program, state Medicaid rules, and how to appeal a denial.

Keeping your body hydrated is critical on GLP-1 medicatio

Injection-site reactions and worsening of pre-existing diabetic retinopathy are also relevant clinical concerns

We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound)

At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems